Overview

Allogeneic SCT of NiCord®, UCB-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients With Hemoglobinopathies

Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Patients with Hemoglobinopathies
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Gamida Cell ltd